Metabolic phenotyping and cardiovascular disease: an overview of evidence from epidemiological settings. Issue 14 (19th February 2021)

• Record Type: Journal Article
• Authors: Iliou, Aikaterini; Mikros, Emmanuel; Karaman, Ibrahim; Elliott, Freya; Griffin, Julian L; Tzoulaki, Ioanna; Elliott, Paul
• Is Part Of: Heart. Volume 107:Issue 14(2021)
• Page Start: 1123
• Page End: 1129
• Publication Date: 2021-02-19
• Subjects: epidemiology -- coronary artery disease -- research design -- biomarkers -- stroke; Heart -- Diseases -- Treatment -- Periodicals; Cardiology -- Periodicals; 616.12
• DOI: 10.1136/heartjnl-2019-315615
• Languages: English
• ISSNs: 1355-6037

Abstract

Abstract : Metabolomics, the comprehensive measurement of low-molecular-weight molecules in biological fluids used for metabolic phenotyping, has emerged as a promising tool to better understand pathways underlying cardiovascular disease (CVD) and to improve cardiovascular risk stratification. Here, we present the main methodologies for metabolic phenotyping, the methodological steps to analyse these data in epidemiological settings and the associated challenges. We discuss evidence from epidemiological studies linking metabolites to coronary heart disease and stroke. These studies indicate the systemic nature of CVD and identify associated metabolic pathways such as gut microbial cometabolism, branched-chain amino acids, glycerophospholipid and cholesterol metabolism, as well as activation of inflammatory processes. Integration of metabolomic with genomic data can provide new evidence for involved biochemical pathways and potential for causality using Mendelian randomisation. The clinical utility of metabolic biomarkers for cardiovascular risk stratification in healthy individuals has not yet been established. As sample sizes with high-dimensional molecular data increase in epidemiological settings, integration of metabolomic data across studies and platforms with other molecular data will lead to new understanding of the metabolic processes underlying CVD and contribute to identification of potentially novel preventive and pharmacological targets. Metabolic phenotyping offers a powerful tool in the characterisation of the molecular signatures of CVD, paving the way to new mechanistic understanding and therapies, as well as improving risk prediction of CVD patients. However, there are still challenges to face in order to contribute to clinically important improvements in CVD.